HAE Haemonetics (HAE) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000313143
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
168
13F, latest reported quarter
Haemonetics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for HAEMONETICS CORP in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 15, 2022.
- The trade is 5.7% of the 24,757 shares held after it.
- No other insider bought within 30 days.
- 168 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KROLL MARK W bought about $98.8K of HAE on Nov 10, 2025, the largest insider purchase at the company on our record; 168 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on May 29, 2024.
- The trade is 23.7% of the 18,196 shares held after it.
- 1 other insider sold within 30 days.
- 168 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, Global Hospital Strong Stewart W sold about $393.0K of HAE on Jul 26, 2024; 1 other insider sold within 30 days and 168 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jul 11, 2024.
- The trade is 0.4% of the 21,331 shares held after it.
- 1 other insider sold within 30 days.
- 168 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Technology Officer Lingamneni Anila sold about $7.1K of HAE on Jul 12, 2024; 1 other insider sold within 30 days and 168 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on May 6, 2024.
- The trade is 10.0% of the 21,410 shares held after it.
- 1 other insider sold within 30 days.
- 168 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Technology Officer Lingamneni Anila sold about $192.2K of HAE on Jul 11, 2024; 1 other insider sold within 30 days and 168 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on May 20, 2024.
- The trade is 13.1% of the 31,257 shares held after it.
- 3 other insiders sold within 30 days.
- 168 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP and General Counsel Basil Michelle L sold about $362.6K of HAE on May 29, 2024; 3 other insiders sold within 30 days and 168 funds added in the latest 13F quarter.56 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
168 funds bought in last quarter
more than 79% of Medical Devices
Revenue
-2.0% year over year
below 80% of Medical Devices
Margin
7.3% net margin
more than 77% of Medical Devices
Buybacks
$175.0M repurchased, FY to 2026-03-28
more than 69% of Medical Devices
Short interest
6.8% of the float short (float per yahoo 2026-10-26) · 5.3 days to cover · settled 2026-09-30
more than 76% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HAE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+132.1%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HAE: institutional holders (13F)
13F holdings, latest reported quarter
5,909,258 sh
$443.2M
4,179,443 sh
$313.5M
2,546,394 sh
$191.0M
2,266,489 sh
$165.0M
2,060,966 sh
$154.6M
Congress trades in HAE
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HAE planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HAE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
EUBEL BRADY & SUTTMAN INCOME AND APPRECIATION FUND
$5.2M position · as of 2026-07-31
3.3%
Miller Market Neutral Income Fund
$10.5M position · as of 2026-07-31
2.9%
Touchstone Funds Group Trust-Touchstone Small Cap Fund
$7.1M position · as of 2026-06-30
2.8%
Touchstone Variable Series Trust-Touchstone Small Company Fund
$1.8M position · as of 2026-06-30
2.7%
Touchstone Strategic Trust-Touchstone Small Company Fund
$46.1M position · as of 2026-06-30
2.7%
DEAN SMALL CAP VALUE
$4.6M position · as of 2026-06-30
2.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Christopher A. Simon
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$12.0M
$8.1M
$3.4M
-52%
-35%
2024
$10.7M
$1.3M
$2.5M
-37%
+21%
2023
$11.5M
$10.2M
$2.8M
-15%
+29%
2022
$10.7M
$18.1M
$2.4M
-18%
+37%
2021
$8.7M
-$2.4M
$2.9M
-37%
+67%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 168 funds added last quarter. Each figure is a federal filing, dated the day it went public.
HAE financials
Revenue growth
-2.0%
XBRL, annual
Net margin
7.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.4B
four quarters, 2025-06-29 to 2026-06-27
Revenue, TTM HAE
| FY Mar 2026 | $1.3B |
| FY Mar 2025 | $1.4B |
| FY Mar 2024 | $1.3B |
| FY Apr 2023 | $1.2B |
| FY Apr 2022 | $993.2M |
| Jun 2026 | $339.4M |
| Mar 2026 | $346.4M |
| Dec 2025 | $339.0M |
| Sep 2025 | $327.3M |
| Jun 2025 | $321.4M |
| Mar 2025 | $330.6M |
| Dec 2024 | $348.5M |
| Sep 2024 | $345.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-0.1%
net income over revenue, 2025-06-29 to 2026-06-27
Net margin, TTM HAE
| FY Mar 2026 | +0.0% |
| FY Mar 2025 | +0.0% |
| FY Mar 2024 | +9.0% |
| FY Apr 2023 | +9.9% |
| FY Apr 2022 | +4.4% |
| Jun 2026 | +9.7% |
| Mar 2026 | -33.9% |
| Dec 2025 | +13.2% |
| Sep 2025 | +11.8% |
| Jun 2025 | +10.6% |
| Mar 2025 | -33.1% |
| Dec 2024 | +10.8% |
| Sep 2024 | +9.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$291.2M
operating cash flow minus capex, 2025-06-29 to 2026-06-27
Free cash flow, TTM HAE
| FY Mar 2026 | $260.4M |
| FY Mar 2025 | $142.4M |
| FY Mar 2024 | $143.6M |
| FY Apr 2023 | $81.7M |
| FY Apr 2022 | $75.8M |
| Jun 2026 | $44.4M |
| Mar 2026 | $53.3M |
| Dec 2025 | $87.2M |
| Sep 2025 | $106.3M |
| Jun 2025 | $13.6M |
| Mar 2025 | $100.9M |
| Dec 2024 | $35.2M |
| Sep 2024 | $39.4M |
At each fiscal year end
Single quarter
Debt to equity
1.40x
long-term 2026-06-27 plus current 2026-06-27; equity 2026-06-27
Debt to equity HAE
| FY Mar 2026 | 1.54x |
| FY Mar 2025 | 1.49x |
| FY Mar 2024 | 0.84x |
| FY Apr 2023 | 0.94x |
| FY Apr 2022 | 1.03x |
| Jun 2026 | 1.40x |
| Mar 2026 | 1.54x |
| Dec 2025 | 1.34x |
| Sep 2025 | 1.44x |
| Jun 2025 | 1.39x |
| Mar 2025 | 1.49x |
| Dec 2024 | 1.35x |
| Sep 2024 | 1.39x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.28x
TTM operating cash flow over long-term 2026-06-27 plus current 2026-06-27
Cash flow to debt HAE
| FY Mar 2026 | 0.24x |
| FY Mar 2025 | 0.15x |
| FY Mar 2024 | 0.22x |
| FY Apr 2023 | 0.36x |
| FY Apr 2022 | 0.22x |
| Jun 2026 | 0.28x |
| Mar 2026 | 0.24x |
| Dec 2025 | 0.28x |
| Sep 2025 | 0.24x |
| Jun 2025 | 0.18x |
| Mar 2025 | 0.15x |
| Dec 2024 | 0.11x |
| Sep 2024 | 0.07x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-0.1%
TTM net income over average of 2025-06-28 and 2026-06-27
Return on equity HAE
| FY Mar 2026 | +0.0% |
| FY Mar 2025 | +0.0% |
| FY Mar 2024 | +13.2% |
| FY Apr 2023 | +14.7% |
| FY Apr 2022 | +5.9% |
| Jun 2026 | -0.1% |
| Mar 2026 | +0.0% |
| Dec 2025 | +0.9% |
| Sep 2025 | +0.1% |
| Jun 2025 | -0.5% |
| Mar 2025 | +0.0% |
| Dec 2024 | +14.1% |
| Sep 2024 | +14.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-0.0%
TTM net income over average of 2025-06-28 and 2026-06-27
Return on assets HAE
| FY Mar 2026 | +0.0% |
| FY Mar 2025 | +0.0% |
| FY Mar 2024 | +5.7% |
| FY Apr 2023 | +6.1% |
| FY Apr 2022 | +2.4% |
| Jun 2026 | -0.0% |
| Mar 2026 | +0.0% |
| Dec 2025 | +0.3% |
| Sep 2025 | +0.0% |
| Jun 2025 | -0.2% |
| Mar 2025 | +0.0% |
| Dec 2024 | +5.5% |
| Sep 2024 | +5.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+6.7%
operating income after a 26.2% effective tax rate, over long-term 2026-06-27 plus current 2026-06-27 plus average of 2025-06-28 and 2026-06-27 minus cash
Return on invested capital HAE
| FY Mar 2026 | +6.8% |
| FY Mar 2025 | +9.4% |
| FY Mar 2024 | +8.7% |
| FY Apr 2023 | +10.0% |
| FY Apr 2022 | +4.3% |
| Jun 2026 | +6.7% |
| Mar 2026 | +6.8% |
| Dec 2025 | +10.8% |
| Sep 2025 | +10.5% |
| Jun 2025 | +10.2% |
| Mar 2025 | +9.4% |
| Dec 2024 | +7.5% |
| Sep 2024 | +7.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+8.0%
operating income (EBIT proxy) over average of 2025-06-28 and 2026-06-27 minus current liabilities
Return on capital employed HAE
| FY Mar 2026 | +7.9% |
| FY Mar 2025 | +11.8% |
| FY Mar 2024 | +9.2% |
| FY Apr 2023 | +10.1% |
| FY Apr 2022 | +5.4% |
| Jun 2026 | +8.0% |
| Mar 2026 | +7.9% |
| Dec 2025 | +11.9% |
| Sep 2025 | +11.7% |
| Jun 2025 | +11.2% |
| Mar 2025 | +11.8% |
| Dec 2024 | +8.6% |
| Sep 2024 | +8.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
57.58x
close 2026-10-26 over four quarters of diluted EPS, 2025-06-29 to 2026-06-27
P/E, trailing HAE
| FY Mar 2026 | 26.36x |
| FY Mar 2025 | 19.09x |
| FY Mar 2024 | 37.27x |
| FY Apr 2023 | 37.11x |
| FY Apr 2022 | 76.01x |
| Jun 2026 | 37.34x |
| Mar 2026 | 26.36x |
| Dec 2025 | 22.12x |
| Sep 2025 | 14.08x |
| Jun 2025 | 22.57x |
| Mar 2025 | 19.09x |
| Dec 2024 | 30.54x |
| Sep 2024 | 33.11x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$6.4B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-27 plus current 2026-06-27, minus cash 2026-06-27
Enterprise value HAE
| FY Mar 2026 | $3.5B |
| FY Mar 2025 | $4.1B |
| FY Mar 2024 | $5.0B |
| FY Apr 2023 | $4.7B |
| FY Apr 2022 | $3.8B |
| Jun 2026 | $4.5B |
| Mar 2026 | $3.5B |
| Dec 2025 | $4.6B |
| Sep 2025 | $3.2B |
| Jun 2025 | $4.5B |
| Mar 2025 | $4.1B |
| Dec 2024 | $4.8B |
| Sep 2024 | $5.0B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield HAE
| FY Mar 2026 | +10.4% |
| FY Mar 2025 | +4.5% |
| FY Mar 2024 | +3.3% |
| FY Apr 2023 | +2.0% |
| FY Apr 2022 | +2.3% |
| Jun 2026 | +8.3% |
| Mar 2026 | +10.4% |
| Dec 2025 | +8.2% |
| Sep 2025 | +11.0% |
| Jun 2025 | +5.3% |
| Mar 2025 | +4.5% |
| Dec 2024 | +2.5% |
| Sep 2024 | +1.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -37%, PEG needs growth
PEG, trailing HAE
| FY Mar 2026 | n/a |
| FY Mar 2025 | 0.43x |
| FY Mar 2024 | 13.85x |
| FY Apr 2023 | 0.22x |
| FY Apr 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 0.52x |
| Sep 2025 | 0.34x |
| Jun 2025 | 0.48x |
| Mar 2025 | 0.43x |
| Dec 2024 | 9.39x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-03 | 2025-03 | 2024-03 | 2023-04 | |
|---|---|---|---|---|
| Revenue | $1.3B | $1.4B | $1.3B | $1.2B |
| Gross profit | $787.6M | $749.0M | $691.5M | $615.1M |
| Operating income | $156.7M | $221.8M | $164.9M | $156.0M |
| Net income | $97.3K | $167.7K | $117.6M | $115.4M |
| EPS (diluted) | n/a | n/a | 2.29 | 2.24 |
| Operating cash flow | $293.2M | $181.7M | $181.8M | $273.1M |
| Cash | $245.4M | $306.8M | $178.8M | $284.5M |
| Long-term debt | $1.2B | $921.2M | $797.6M | $754.1M |
| Buybacks | $175.0M | $225.0M | $0 | $75.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
HAE Stock Sonar score 5/7 axes
Find similar shapesCompareHAE ranks highest on institutional and government (79th percentile) and profitability (61st), and lowest on growth (18th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
